Enrollment for Pharmacyclics' Phase III study using ibrutinib in CLL patients ... News-Medical.net ... planned 110 patients in the Phase II single-arm study using ibrutinib in patients with mantle cell lymphoma (MCL) who progress after bortezomib therapy and have received at least one prior rituximab-containing chemotherapy regimen, SPARK (MCL2001). |
